查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858087

止吐药市场按适应症、药物类别、给药途径、最终用户和分销管道划分－2025-2032年全球预测

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，止吐药市场规模将达到 117.8 亿美元，复合年增长率为 8.97%。

关键市场统计数据
基准年 2024 59.2亿美元
预计年份：2025年 64.4亿美元
预测年份 2032 117.8亿美元
复合年增长率 (%) 8.97%

介绍止吐药物，重点阐述其临床重要性、不断变化的患者需求以及创新与支持性护理的交汇点。

止吐药物处于临床治疗、病患体验和商业策略的交会点。在现代肿瘤学、手术全期护理和放射治疗中，人们不仅关注临床疗效，也重视药物的耐受性和生活质量，这使得止吐药物在治疗路径中的作用从辅助手段提升至核心地位。因此，临床医生、支付方和医疗服务提供者正在从更广泛的角度评估止吐药物的选择，包括给药的便利性、安全性以及与多模式支持治疗方案的整合。

此外，医疗服务模式的变革，例如门诊化疗、居家输液服务和日间手术中心的扩展，正在改变人们对给药途径和产品包装的期望。患者和临床医生都在寻求可靠的口服药物，既能保持疗效，又能确保患者在院外也能坚持用药；而医疗系统则优先考虑能够减少患者再次入院率并提高医疗服务效率的干预措施。因此，製造商和经销商必须调整其商业模式，以适应不断变化的采购流程和临床医生的工作流程。

最后，监管细则的澄清和指南的更新正在加强循证处方，而报销和合约环境也持续影响处方决策。总而言之，这些因素既给开发商、医疗服务提供者和医疗系统带来了挑战，也带来了机会，帮助他们改善支持性照护效果和营运效率。

止吐疗法的变革性转变：药物创新、数位化医疗整合与治疗模式变革

止吐药物领域正经历巨大的变革时期，这主要得益于药理学、製剂和治疗模式的进步。近年来，更多标靶性药物和组合方案的研发，在提高止吐疗效的同时，显着降低了副作用。这些药理学创新与改进的製剂相辅相成，提高了口服生物有效性并延长了治疗持续时间。因此，临床医生现在可以根据治疗强度、患者合併症和实际操作限制，选择更合适的治疗方案。

同时，医疗模式正朝着以病人为中心的方向转变。远端医疗追踪、远距症状监测和数位化依从性工具正被越来越多地用于了解患者在实际环境中的耐受性，并指导支持性干预措施。这些数位化辅助工具能够更早发现突破性噁心，并及时升级或调整止吐治疗方案，从而改善治疗效果，减轻急诊服务的负担。同时，供应链韧性和策略采购正成为製造商和医疗系统的优先事项，促使他们投资于本地製造能力和多元化的供应商网路。

此外，总医疗成本指标和病患报告结局已成为支付方和医院筹资策略的核心。这种转变有利于减少后续资源利用的干预措施，例如减少非计划门诊就诊和延长住院时间，从而提升那些能够显着改善耐受性和依从性的止吐药的商业价值。总而言之，这些转变正在重塑临床实践和竞争格局，要求相关人员调整其研发、市场准入和商业化策略。

评估2025年美国关税对止吐药供应链、定价权、策略采购及生产韧性的累积影响

2025年的关税情势预示着包括止吐药在内的各类药品供应链优化和商业规划将面临新的挑战。进口关税和贸易政策的调整加剧了对全球筹资策略的审查，迫使製造商重新评估活性药物原料药、辅料和成品的生产地点。为此，多家公司加快了紧急时应对计画的实施，以减少对单一国家供应节点的依赖，并降低价格和前置作业时间的波动风险。

因此，采购团队和委託製造製造商已将供应商多元化和双重采购安排列为优先事项，以确保供应的连续性。这些措施包括对区域製造外包进行资格认证、增加关键零件的库存缓衝以及重新谈判长期合约以纳入关税应急条款。同时，监管和品质监督仍然是重中之重。本地化工作必须符合严格的製造标准，同时最大限度地减少对现有监管备案和分销协议的影响。

从策略角度来看，企业正在采取多种风险缓解策略，包括将部分生产环节转移到近岸地区、投资供应链可视性工具以及与分销合作伙伴紧密合作以优化市场通路物流。同时，支付方和医疗系统越来越重视可预测的供应和稳定的价格，并将此作为纳入药品目录和优先签约的标准。总而言之，2025年累积关税的影响将强化企业采取具有韧性、透明且区域平衡的生产和筹资策略的奖励。

将适应症、药物类别、给药途径、终端用户行为和分销管道联繫起来，形成可操作的细分洞察，从而指导策略制定。

市场细分为将临床需求转化为产品、市场准入和商业策略提供了一个实用的架构。基于适应症的市场动态因化疗引起的噁心呕吐、术后噁心呕吐和放疗引起的噁心呕吐而异，每种适应症都有其独特的疗效、用药时机和安全性要求。化疗相关方案通常需要多药预防和可预测的药物动力学，而术后用药则强调起效迅速和适合短期住院，放疗相关的噁心可能需要延长给药时间并采用分次给药方案。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大专为儿科和老年患者设计的口服Ondansetron製剂的市场
  • 提高药物基因体学资料的整合度，以实现癌症患者止吐治疗的个人化。
  • 为对抗化疗引起的噁心，神经激肽-1受体拮抗剂的研究正在加速推进。
  • 生技公司与学名药生产商进行策略合作，共同开发高性价比的止吐药物
  • 数位化用药依从性工具和行动应用程式的快速涌现，有助于提高止吐治疗方案的依从性。
  • 对标靶中枢催吐通路肽类止吐候选药物的投资不断增长
  • COVID-19 供应链中断对新兴市场注射止吐药供应的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依适应症分類的止吐药市场

  • 化疗引起的噁心和呕吐
  • 术后噁心呕吐
  • 放射线引起的噁心和呕吐

9. 按药物类别分類的止吐药市场

  • 皮质类固醇
  • 多巴胺拮抗剂
  • 神经激肽1受体拮抗剂
  • 血清素5-HT3受体拮抗剂

第十章 依给药途径分類的止吐药市场

  • 静脉
  • 口服

第十一章 依最终用户分類的止吐药市场

  • 诊所
  • 居家照护
  • 医院

第十二章：止吐药市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：各地区止吐药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 止吐药市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国止吐药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Helsinn Healthcare SA
    • Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C996F2

The Antiemetic Drugs Market is projected to grow by USD 11.78 billion at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.92 billion
Estimated Year [2025] USD 6.44 billion
Forecast Year [2032] USD 11.78 billion
CAGR (%) 8.97%

Introduces antiemetic therapeutics, highlighting clinical importance, evolving patient needs, and the intersection of innovation and supportive care

Antiemetic therapeutics sit at the intersection of clinical care, patient experience, and commercial strategy. Modern oncology, perioperative medicine, and radiation therapy increasingly emphasize not only clinical efficacy but also tolerability and quality of life, elevating the role of antiemetics from supportive adjuncts to core components of treatment pathways. As a result, clinicians, payers, and providers now evaluate antiemetic choices through a broader lens that includes administration convenience, safety profiles, and integration with multimodal supportive care protocols.

Moreover, shifts in care delivery-most notably the expansion of outpatient chemotherapy, home-based infusion services, and ambulatory surgery centers-have altered expectations for route of administration and product packaging. Patients and clinicians demand reliable oral options that preserve efficacy while enabling adherence outside the hospital, and health systems prioritize interventions that reduce readmissions and improve throughput. Consequently, manufacturers and distributors must adapt commercial models to align with evolving procurement processes and clinician workflows.

Finally, regulatory clarity and guideline updates have reinforced evidence-driven prescribing, while reimbursement and contracting environments continue to shape formulary decisions. Taken together, these forces create both constraints and opportunities for developers, suppliers, and health systems seeking to improve supportive care outcomes and operational efficiency.

Transformative shifts in antiemetic therapy driven by pharmacologic innovation, digital care integration, and changing delivery models

The antiemetic landscape is undergoing substantive transformation driven by advances in pharmacology, formulation science, and care delivery models. Recent years have produced more targeted agents and combination regimens that enhance emetic control while reducing adverse effects, and these pharmacologic innovations are complemented by formulation improvements that expand oral bioavailability and prolong therapeutic windows. As a result, clinicians can select regimens that better match treatment intensity, patient comorbidities, and logistical constraints.

Concurrently, care models are shifting toward patient-centric approaches. Telehealth-enabled follow-up, remote symptom monitoring, and digital adherence tools are increasingly used to capture real-world tolerability and to guide supportive interventions. These digital adjuncts allow for earlier identification of breakthrough nausea and enable timely escalation or modification of antiemetic therapy, improving outcomes and reducing the burden on acute care services. Parallel to this, supply chain resilience and strategic sourcing have risen as priorities for manufacturers and health systems, prompting investment in regional manufacturing capacity and diversified supplier networks.

In addition, payer and hospital procurement strategies now center on total cost of care metrics and patient-reported outcomes. This change favors interventions that reduce downstream resource utilization, such as unscheduled clinic visits and prolonged hospital stays, thereby elevating the commercial value of antiemetics that demonstrably improve tolerability and adherence. Collectively, these shifts are reshaping clinical practice and the competitive landscape, requiring stakeholders to realign R&D, market access, and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on antiemetic supply chains, pricing dynamics, strategic sourcing, and manufacturing resilience

The tariff landscape introduced in 2025 ushered in a new set of variables for supply chain optimization and commercial planning across pharmaceutical categories, including antiemetics. Import duties and trade policy adjustments have increased scrutiny of global sourcing strategies, prompting manufacturers to re-evaluate where active pharmaceutical ingredients, excipients, and finished-dose manufacturing occur. In response, several firms accelerated contingency planning to reduce dependence on single-country supply nodes and to mitigate price and lead-time volatility.

Consequently, procurement teams and contract manufacturers have prioritized supplier diversification and dual-sourcing arrangements to preserve continuity of supply. These actions include qualification of regional contract manufacturing organizations, increased inventory buffering for critical components, and renegotiation of long-term contracts to incorporate tariff contingency clauses. At the same time, regulatory and quality oversight remain central; localization efforts must satisfy stringent manufacturing standards while minimizing disruptions to existing regulatory filings and distribution agreements.

From a strategic perspective, companies have adopted multiple risk-mitigation tactics that include nearshoring select production steps, investing in supply visibility tools, and coordinating closely with distribution partners to optimize route-to-market logistics. Payers and health systems, for their part, are increasingly focused on predictable supply and stable pricing as criteria for formulary placement and preferred contracting. In sum, the cumulative tariff impacts of 2025 have strengthened incentives for resilient, transparent, and regionally balanced manufacturing and procurement strategies.

Actionable segmentation insights connecting indication, drug class, administration route, end user behavior, and distribution channel guidance for strategy

Segmentation provides a practical framework to translate clinical needs into product, access, and commercial strategies. Based on Indication, market dynamics differ across chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and radiation-induced nausea and vomiting, each presenting unique efficacy, timing, and safety imperatives. Chemotherapy-associated protocols often require multi-agent prophylaxis and predictable pharmacokinetics; post-operative use emphasizes rapid onset and suitability for short-stay settings; radiation-related nausea may demand extended-duration control for fractionated regimens.

Based on Drug Class, decision criteria and formulary placement pivot on attributes of corticosteroids, dopamine antagonists, neurokinin 1 receptor antagonists, and serotonin 5-HT3 receptor antagonists, with each class offering distinct benefit-risk trade-offs that influence regimen selection and combination approaches. Corticosteroids provide broad antiemetic augmentation but carry systemic effects that must be managed. Dopamine antagonists supply alternative mechanisms but demand attention to neurologic tolerability. Neurokinin 1 receptor antagonists and serotonin 5-HT3 receptor antagonists remain foundational for guideline-driven prophylaxis, and evolving formulations aim to optimize adherence and convenience.

Based on Route Of Administration, outcomes and channel strategies diverge between intravenous and oral options, shaping procurement preferences in hospitals and outpatient settings and influencing product development priorities. Based on End User, clinics, home care settings, and hospitals each impose different stocking practices, dispensing workflows, and clinician touchpoints that affect uptake and adherence. Based on Distribution Channel, hospital pharmacy, online pharmacy, and retail pharmacy routes carry distinct reimbursement pathways, inventory models, and patient access considerations that determine where and how products gain traction. By integrating these segmentation lenses, stakeholders can align clinical evidence generation, commercial messaging, and distribution tactics to the real-world requirements of each use case.

Regional insights on how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics influence access, reimbursement, distribution, and clinical adoption

Regional dynamics materially influence every aspect of antiemetic development, approval, distribution, and adoption. In the Americas, diverse payer landscapes and a mix of public and private procurement systems create incentives for evidence demonstrating reductions in downstream healthcare utilization; consequently, formulary positioning often hinges on total cost of care narratives and supply reliability. In North America, outpatient oncology and ambulatory surgery growth have elevated demand for convenient oral options and compact packaging suited to home administration.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and national procurement processes shape entry strategies, with reimbursement timelines and health technology assessment outcomes guiding commercialization sequencing. Local manufacturing and distribution partnerships frequently reduce lead times and support compliance with regional procurement rules, and in some countries system-level purchasing emphasizes affordable, generic-friendly options.

In Asia-Pacific, rapid expansion of oncology services, increased uptake of outpatient care models, and heterogeneous regulatory pathways present both opportunity and complexity. Investment in regional manufacturing infrastructure and strategic partnerships can accelerate access, while tailored clinical evidence that reflects local treatment paradigms supports uptake. Across all regions, distribution channel evolution and digital health adoption vary markedly, and stakeholders must calibrate pricing, stakeholder engagement, and supply strategies to local drivers to secure sustainable access and clinical integration.

Key company insights examining competitive positioning, R&D priorities, strategic partnerships, manufacturing footprint, and commercialization strategies

Competitive dynamics in the antiemetic space reflect a blend of established therapeutic classes, generics competition, and incremental innovation through new formulations and combination regimens. Companies that sustain differentiated value propositions-whether through long-acting formulations, fixed-dose combinations, or convenience-focused packaging-tend to secure preferential procurement and clinician loyalty. Strategic partnerships across development, manufacturing, and distribution channels further accelerate market entry and reduce execution risk.

R&D priorities now emphasize not only mechanistic efficacy but also tolerability, dosing convenience, and evidence of downstream healthcare savings. This shift has stimulated cross-functional collaborations between clinical teams and real-world evidence groups to capture patient-reported outcomes and healthcare utilization endpoints. In addition, manufacturing footprint and supply chain transparency have become competitive differentiators; companies that can demonstrate robust, diversified supply and quick replenishment capabilities gain favor with large hospital systems and integrated delivery networks.

Commercial models increasingly blend direct-to-provider engagement, digital tools to support patient adherence, and targeted contracting with payers and group purchasing organizations. Firms that articulate clear value across clinical, operational, and economic dimensions, and that can adapt to regional procurement nuances, will be better positioned to convert clinical advantage into sustainable commercial performance.

Actionable recommendations to strengthen supply resilience, accelerate adoption, optimize distribution, and prioritize patient-centric innovation

Leaders should prioritize a short set of high-impact actions to preserve access, support clinicians, and capture commercial value. First, reinforce supply chain resilience through supplier diversification, strategic regional partnerships, and inventory visibility tools that enable rapid response to disruption. Second, accelerate development of patient-centric formulations and packaging that support outpatient and home-care administration, thereby aligning product attributes with evolving care pathways.

Third, invest in evidence generation that demonstrates not only symptom control but also reductions in downstream resource use and improvements in patient-reported outcomes; such evidence strengthens negotiations with payers and hospital procurement teams. Fourth, deploy digital adherence and remote monitoring solutions to support real-world use, reduce breakthrough events, and collect post-launch data that inform iterative product positioning. Fifth, refine commercial approaches to suit distribution channels-hospital pharmacy, online pharmacy, and retail pharmacy-ensuring that reimbursement, logistics, and clinician engagement align with channel-specific expectations.

Finally, integrate tariff and trade policy risk into strategic planning by considering nearshoring, contractual tariff protections, and scenario-based financial modeling. By sequencing these actions with clear owners and measurable KPIs, organizations can move from reactive to proactive management of clinical, operational, and commercial risks.

Robust research methodology combining primary expert engagement, structured secondary review, data triangulation, validation, and limitation disclosure

The analysis underpinning this report integrates structured primary and secondary research practices to ensure methodological rigor and practical relevance. Primary inputs include interviews with clinical experts, procurement leaders, and commercial executives to capture experiential insights on prescribing behavior, purchasing priorities, and supply chain constraints. Secondary review comprises peer-reviewed literature, clinical guideline analyses, regulatory documentation, and publicly available policy statements to contextualize clinical and policy drivers.

Data triangulation is applied across sources to validate thematic findings and to reconcile divergent perspectives. Quality controls included standardized interview guides, independent coding of qualitative inputs, and cross-verification of critical claims with multiple expert respondents. Limitations are acknowledged, including potential variability in regional practice patterns and the evolving nature of policy interventions. These limitations are disclosed transparently, and findings are presented with caveats where applicable to support informed decision-making.

Concise conclusion synthesizing strategic imperatives, priorities, and considerations to guide stakeholders through antiemetic challenges and opportunities

The antiemetic therapeutic area presents a convergence of clinical need, delivery model change, and commercial complexity that demands strategic clarity. Stakeholders who align product attributes with evolving care settings-particularly outpatient and home-based administration-while reinforcing supply resilience will be better positioned to meet clinician and payer expectations. Meanwhile, evidence generation that quantifies patient-centered benefits and operational savings remains a powerful lever for formulary inclusion and contracting.

Looking ahead, organizations should balance near-term operational actions with longer-term investments in formulation innovation and digital support tools. By doing so, they can reduce acute care utilization, improve patient adherence, and create defensible differentiation against generic competition. Ultimately, the most successful stakeholders will be those that integrate clinical insight, supply chain agility, and pragmatic commercialization into a cohesive strategy that responds to both immediate pressures and enduring patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding market for oral dissolvable ondansetron formulations tailored to pediatric and geriatric patients
  • 5.2. Increasing integration of pharmacogenomics data to personalize antiemetic therapy in oncology patients
  • 5.3. Surge in research on neurokinin-1 receptor antagonists addressing breakthrough chemotherapy-induced nausea
  • 5.4. Strategic partnerships between biotech firms and generics manufacturers to co-develop cost effective antiemetic solutions
  • 5.5. Rapid emergence of digital adherence tools and mobile apps enhancing patient compliance with antiemetic regimens
  • 5.6. Growing investment in peptide based antiemetic candidates targeting central vomiting pathways
  • 5.7. Impact of COVID-19 supply chain disruptions on availability of injectable antiemetic drugs in emerging markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiemetic Drugs Market, by Indication

  • 8.1. Chemotherapy-Induced Nausea And Vomiting
  • 8.2. Post-Operative Nausea And Vomiting
  • 8.3. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Drug Class

  • 9.1. Corticosteroids
  • 9.2. Dopamine Antagonists
  • 9.3. Neurokinin 1 Receptor Antagonists
  • 9.4. Serotonin 5-HT3 Receptor Antagonists

10. Antiemetic Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Antiemetic Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Antiemetic Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antiemetic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiemetic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiemetic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Helsinn Healthcare SA
    • 16.3.3. Hoffmann-La Roche AG
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Novartis AG
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Dr. Reddy's Laboratories Ltd.
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIEMETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 333. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. FRANCE